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ABSTRACT
Loss of imprinting (LOI) is the reactivation of
the silenced allele of an imprinted gene, leading to
perturbation of monoallelic expression. We tested
the hypothesis that LOI of PLAGL1, a representative
maternally imprinted gene, occurs through an
all-or-none process leading to a mixture of fully
imprinted and nonimprinted cells. Herein using
a quantitative RT-PCR-based experimental
approach, we measured LOI at the single cell level
in human trophoblasts and demonstrated a broad
distribution of LOI among cells exhibiting LOI, with
the mean centered at  100% LOI. There was a sig-
nificant (P<0.01) increase in expression after 2 days
of 5-aza-20-deoxycytidine (AZA) treatment and a
significant (P<0.01) increase in LOI after both 1
and 2 days of AZA treatment, while the distribution
remained broad and centered at  100% LOI. We
propose a transcriptional pulsing model to show
that the broadness of the distribution reflects the
stochastic nature of expression between the two
alleles in each cell. The mean of the distribution of
LOI in the cells is consistent with our hypothesis
that LOI occurs by an all-or-none process. All-or-
none LOI could lead to a second distinct cell popu-
lation that may have a selective advantage, leading
to variation of LOI in normal tissues, such as the
placenta, or in neoplastic cells.
INTRODUCTION
Genomic imprinting is the silencing of one parental allele
in the zygotes of gametes leading to monoallelic expres-
sion of the gene in the oﬀspring (1). Several epigenetic
processes such as DNA methylation and histone modiﬁ-
cation regulate this sex-dependent pattern of gene expres-
sion (1). Most of the imprinted genes in mammals control
tissue growth (2). The most predominant hypothesis to
explain such conservation is the ‘parental conﬂict hypoth-
esis’ (3). This hypothesis proposes that the purpose of the
imprinting is to assure appropriate allocation of limited
maternal resources to each conceptus. Perturbations of
genomic imprinting, i.e. loss of imprinting (LOI), have
been implicated in multiple human diseases, including
reproductive abnormalities and cancer (4–7). In previous
work, we have demonstrated variation of LOI for many
paternally or maternally expressed genes among human
placentas (8). In this study, we examined the mechanism
of LOI by measuring cell-to-cell variation in imprinting
status.
PLAGL1 encodes a zinc ﬁnger protein that is thought to
function as a transcription factor, inducing apoptosis and
cell cycle arrest at G1 phase (9). PLAGL1 is a paternally
expressed (maternally imprinted) gene that belongs to an
imprinting cluster located on chromosome 6q24 (10). It is
polymorphically imprinted in diﬀerent tissues; monoallelic
expression has been shown in various human tissues
(placenta, muscle, lung), while it is biallelically expressed
in peripheral blood leukocytes (11,12). Dysregulation of
PLAGL1 has been observed in ovarian and breast cancer
cells, while paternal uniparental disomy of 6q24 has been
implicated in transient neonatal diabetes mellitus (13–15).
We selected PLAGL1 as our reference gene to study the
mechanism of LOI, because PLAGL1 was among the
most highly expressed imprinted genes that we had
assayed in our previous work and our cell line was
heterozygous for the readout polymorphism, a prerequi-
site for the LOI measurement.
PLAGL1 has two promoters, but only one is active in
human placentas (11). The inactive promoter is neither
imprinted nor methylated. The active promoter is
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tion in primary human cells at all or the majority of
51 CpG sites compared with lack of methylation at all
or the majority of the sites in the paternal allele (16).
The same type of pattern is seen in cell lines, but with
more variation in methylation between individual
subclones (14). We chose a readout polymorphism
(rs9373409) in the 50-UTR which is represented in all
splice variants (16) and has a minor allele frequency
>22% in all populations.
Stochasticity in transcription has been observed for
many genes in both prokaryotic and eukaryotic cells
(17–19). In previous work, we have shown that stochastic
transcription of biallelically expressed genes in human
cells can lead to cell-to-cell variation in mRNA copy
number by as much as 1000-fold (20), and to imbalanced
transcription between two alleles within single cell (21).
Gene expression noise has a signiﬁcant eﬀect on many
biological processes, contributing to phenotypic variabil-
ity of genetically identical organisms and determining
cellular fate following viral infection (22–26). To be
noted, the measurements of LOI in PLAGL1 at the
single cell level take place in the context of signiﬁcant
transcriptional noise.
Herein, we test the hypothesis that LOI is an all-or-none
phenomenon at the single cell level, wherein partial LOI
in tissue would reﬂect the fraction of cells with complete
LOI. We quantify expression of the paternal and maternal
alleles in single cells from a human placental trophoblast
cell line heterozygous for a readout polymorphism in
PLAGL1 mRNA (8). The PLAGL1 gene is known to be
regulated by DNA methylation and histone modiﬁcation
(14,27). By treating the cell line with 5-aza-20-
deoxycytidine (AZA) or Trichostatin A (TSA), we were
able to examine the mechanism of LOI at the single cell
level under diﬀerent perturbations.
MATERIALS AND METHODS
Cell culture
Primary cytotrophoblasts were extracted from human
term placentas as described earlier (28). Primary
cytotrophoblasts and the placental trophoblast cell line
HTR-8/SV neo (HTR8) (29) were cultured at 37 C
in DMEM and RPMI 1640 media (Gibco), respectively,
supplemented with 10% fetal bovine serum (Hyclone),
100U/ml penicillin and 100mg/ml streptomycin
(Invitrogen).
Cell treatment
HTR8 cells were treated separately with 0.5mM AZA
or 20nM TSA. Fresh cell media and antibiotics were
added every 24h and treated cells were collected after 24
and 48h.
Cell synchronization
HTR8 cells were synchronized at the G1/S border using
double treatment of thymidine as described earlier (30).
Brieﬂy, 2mM of thymidine was added in growing cells
for 12h to accumulate the majority of the cells at G1/S.
Thymidine was replaced by fresh media for 12h and was
added back to the media for 12h. Finally, the thymidine
was removed and cells were collected every 2h for up to
8h. Cell synchronization was validated by FACS using a
LSRII system (BD Bioscience) to separate treated cells
stained by VybrantDyeCycle
TM violet (Invitrogen) fol-
lowing standard protocols.
Nucleic acid extraction and cDNA synthesis
Nucleic acids extraction, DNase treatment and conversion
of total RNA to single-stranded cDNA were performed as
described earlier (8).
Quantitative PCR of total RNAs
cDNAs were ampliﬁed with gene-speciﬁc primers. The
primers are listed in Supplementary Table S1. The expres-
sion levels of PLAGL1, ZNF331 and ACTB genes were
determined by quantitative PCR (qPCR) using the
LightCycler480
TM (Roche). All qPCR assays were
carried out in triplicate in a reaction containing: buﬀer
(50mM Tris–OH+HCl, pH 7.5; 50mM KOAc; 2%
glycerol, 0.1mg/ml BSA); 4mMMg(OAc)2; 0.2mM each
dNTPs (dUTP replacing dTTP); 0.2mM primers; 0.25 
SYBR Green (Invitrogen); 5U/ml AmpliTaq Gold
(Applied Biosystems); 20ng single-stranded cDNA
template; ﬁnal volume 20ml. Cycling conditions for all
genes were: 95.0 C for 10min, followed by 50 cycles of
95.0 C for 30s, 65.0 C for 30s and 72.0 C for 30s. The
crossing point, Cp, was automatically calculated from the
ampliﬁcation curve without human intervention.
Single cell sorting
HTR8 cells and primary cytotrophoblasts were sorted
directly into 384-well PCR plates as described earlier
(21). Brieﬂy, single cells were sorted into 384-well PCR
plates (Roche) using the MoFlo high-speed cell sorter.
Each well contained 5ml cell lysis buﬀer [4mM magnesium
acetate (Sigma), 0.05% NP40 (Sigma), 0.8U/ml Protector
RNAse Inhibitor (Roche Applied Sciences)]. After
sorting, the plates were immediately placed on dry ice
and stored at  70 C for future use.
LOI assay and measurements on total
RNA and single cells
LOI is a measurement of expression of the silenced allele,
which may be calculated as:
LOI ¼ 2 jDCpj
where the |DCp| refers to the absolute diﬀerence between
the allele-speciﬁc Cp values on cDNA level corrected for
the speciﬁcity of the allele-speciﬁc PCR (8).
The conditions for the measurement of the LOI levels
in total RNA level have been described elsewhere (8).
The sequences of the primers used for the ampliﬁcation
of the area bracketing the readout polymorphism and
the quantitative allele-speciﬁc PCR (qASPCR) are listed
in Supplementary Table S1. The SNP reference numbers
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To measure the levels of LOI at the single cell level, a
two-step hemi-nested RT-PCR protocol was carried out.
For the ﬁrst RT-PCR step, an aliquot of 5ml of 2xAccuRT
PCR reaction mix [2xAccuRT buﬀer, 4mM magnesium
acetate, 0.2mM primer sets, control oligonucleotides
(2000 copies/well for PLAGL1 or 200 copies/well for
ZNF331; the sequences of the control oligonucleotides
are given in Supplementary Table S1), 0.2mM each
dNTP (dUTP) and 0.375U/ml AccuRT with aptamer (an
aptamer-based hot-start, magnesium-activated thermo-
stable DNA polymerase kindly provided by Dr Tom
Myers of Roche Molecular Systems)] was added into
each well of a cell-sorted PCR plate. The cycling
conditions were: 65.0 C for 30min (reverse transcription),
followed by 15 cycles of 95.0 C for 15s and 60.0 C for
50s. For the second PCR step, 2ml of the PCR products
from the ﬁrst PCR were mixed with 8ml of PCR reaction
mix [2 Lightcycler Probe Master Mix, 0.2mM ﬁnal
concentrations of allele-speciﬁc primer sets and 0.1mM
ﬁnal concentration of Roche LNA probe]. All the
reactions were run in duplicate. The sequences of the
primers used for the qASPCR are listed in
Supplementary Table S1. We used the Roche LNA
probes #74 and #50 for PLAGL1 and ZNF331 genes,
respectively. The cycling conditions were: 95 C for
10min, followed by 50 cycles of 95 C for 10s, 65 C for
20s and 72 C for 10s.
Accuracy of the LOI measurements
The error of our LOI measurements was determined by
performing the qASPCR assay using serial dilutions of a
genomic DNA mixture from two homozygous individuals
for the PLAGL1 SNP (rs9373409, A/G). The DNA mix
contained G:A copies in a 9:1 ratio (10% LOI). Genomic
DNA was diluted from 6000 copies to 6 copies per
reaction. All the reactions were repeated six times.
Statistical analysis
The statistical analyses were performed using SPSS
version 16.0 (SPSS Inc., Chicago, IL, USA). The Fisher
exact test was used to determine the signiﬁcance of the per-
centage of AZA-treated cells exhibiting LOI compared
with the untreated control. The chi-square test was
utilized to compare the LOI percentage and the expression
of PLAGL1 in RNA from treated versus untreated cells.
The mean and variance of LOI for cells exhibiting LOI
was obtained by bootstrapping using R version 2.90. The
simulation of the distributions of LOI in the all-or-none
LOI and gradient LOI models was computed in R version
2.90. The Kolmogorov–Smirnov test for comparison of
the experimental and simulated distributions was also
performed in R version 2.90.
Model
The model proposes that each allele of a gene at a speciﬁc
time point can be either in an active state, during which
transcription is very eﬃcient, or an inactive state, in which
transcription is hindered. The synthesized mRNA is
proposed to follow an exponential decay. The amount of
total mRNA from each allele (denoted as A1 or A2) at
a certain time ti is given by
A1 ¼
X t1¼ti
t1¼0
pt 1, 1 ðÞ e
t1 ti
k ½   e
"#
 m
A2 ¼
X t2¼ti
t2¼0
pt 2, 2 ðÞ e
t2 ti
k ½   e
"#
 m
where p(t,l) is a hypergeometric random function
determining the transcription state at time t:1=active
or 0=inactive with the pulsing frequency l;  e is a
Gaussian random variable from 0% to 100% for the tran-
scription eﬃciency of each pulse; k is the parameter to
control the mRNA exponential decay rate;  m is a
Gaussian random variable to estimate the measurement
error. We set DCp=0.5 as the SD of  m.
The simplest simulation assumed that every pulse gave
100% transcription eﬃciency so that  e=1. For the all-
or-none LOI model, 10% of the cells were set to follow
transcriptional pulsing on both alleles with pulsing fre-
quency l1=l2=0.2 and 90% of the cells to exhibit
pulsing only for the major allele with pulsing frequency
l1=0.2. For the partial LOI model, we set the minor
allele pulsing frequency to be l2=0.02, 10-fold less than
the pulsing frequency of the major allele. Using the
equations above, we carried out simulations of 200
pulsing steps in 2000 cells.
Furthermore, additional simulations were carried
out with consideration of transcription eﬃciency  e as
a Gaussian random variable at the single cell level
(Supplementary Figure S1A) or with consideration of
only the cells in the top 25% of total mRNA copies
(Supplementary Figure S1B). Both simulations showed
similar distributions to that seen for the simple model.
RESULTS
We tested the hypothesis that LOI was an all-or-none
phenomenon at the single cell level using the maternally
imprinted gene PLAGL1. Figure 1 illustrates the experi-
mental design for studying the eﬀect of treatment of single
HTR8 trophoblasts with AZA. Because of cell-to-cell vari-
ability in gene expression, PLAGL1 expression could only
be measured in a subset of the cells (center panels). LOI in
the PLAGL1 gene in the expressing cells was measured by
examining allele-speciﬁc expression in the presence and
absence of AZA (right panels).
Genomic imprinting is regulated primarily by DNA
methylation and histone modiﬁcation. We treated the
trophoblasts either with AZA, a DNMT1 inhibitor or
TSA, an HDAC inhibitor, and looked at the impact of
these drugs on the PLAGL1 expression and LOI proﬁle on
total RNA. Table 1 shows the relative expression levels of
PLAGL1 and the percent LOI together with conﬁdence
limits for the allele-speciﬁc PCR triplicate measurements.
There was a signiﬁcant (P<0.01) increase in expression
after 2 days of AZA treatment and a signiﬁcant (P<0.01)
increase in LOI after both 1 and 2 days of AZA treatment.
Nucleic Acids Research, 2009,Vol.37, No. 21 7041TSA treatment resulted in no signiﬁcant changes in
expression or LOI.
Single cell measurements are presented in Figure 2.
Figure 2A and B present measurement controls for
primary cytotrophoblasts from individuals homozygous
for the two alleles of the PLAGL1 readout polymorphism.
Because the LOI measurement method cannot detect LOI
in readout polymorphism homozygotes, measured LOI
must reﬂect allele-speciﬁc PCR measurement error.
All their calculated LOI values were between 0% and
35%. To exclude all contributions from monoallelic
expressing cells, we present the distribution of
heterozygous cells exhibiting LOI within the range of
35–100%. The means and the variances for the
distributions were computed by a bootstrapping method.
We found that the mean PLAGL1 LOI measurements of
the AZA treated cells at 0, 1 and 2 days were 87%, 97.2%
and 92.3%, respectively, while the SDs were 7.4%, 7.3%
and 5.8%, respectively. To explore possible bias in the
35% cutoﬀ, we repeated the same analyses using cutoﬀs
of 10 and 20% (Supplementary Table S2). For all the
AZA-treated samples, the mean LOI with each cutoﬀ
was centered at  100% with SDs of 5–9%.
Figure 2C depicts the analysis of LOI for ZNF331,
which is not imprinted in HTR8 cells (31), and whose
expression was between 2- and 4-fold greater than that
of PLAGL1. The mean LOI and standard deviation of
the mean for the nonimprinted gene ZNF331 were
98.6% and 2.2%, respectively. The distributions of LOI
measured for both genes in cells within the selected range
were centered at  100% LOI.
The PCR reaction for PLAGL1 was reproducibly
able to detect six copies of duplex DNA template
Figure 1. Illustration of heterogeneity in the expression and LOI of the PLAGL1 gene. Individual trophoblasts (shown as ovals), either nontreated
(upper panel) or treated with AZA (lower panel) were tested for the expression level of the PLAGL1 gene. We detected PLAGL1 expression only in a
subset of the cells (labeled with Y). The cells expressing PLAGL1 showed diﬀerent LOI levels [shown as a color gradient from dark red (0% LOI) to
light yellow (100% LOI), with a numerical bias toward LOI].
Table 1. LOI% and expression of PLAGL1 on the total RNA level
LOI%
Relative expression
a
( 1000)
(low95%, up95%) (low95%, up95%)
Without treatment
Primary cytotrophoblasts/AG 3.4 (2.8, 4.1)
HTR8/AG 2.3 (0.4, 4.2) 2.1 (1.6, 2.7)
AZA treatment of HTR8/AG
1day 8.4 (5.4, 12.9)** 3.4 (2.8, 4.2)*
2 days 12.7 (9.8, 16.4)** 6.0 (4.9, 7.3)**
TSA treatment of HTR8/AG
1day 2.5 (2.0, 3.0) 3.8 (2.4, 6.0)
2 days 4.4 (3.9, 4.9)* 3.2 (2.5, 4.0)
aNormalized against ACTB.
Treated versus untreated (chi-square): **P<0.01; *P<0.1.
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the single cell level, mRNA expression could only be
detected in 40% of the cells. To test whether expression
of PLAGL1 was dependent on the cell cycle phase, we
compared the PLAGL1 expression levels between cells
with no synchronization and synchronized to G1/S
phase. The synchronization was conﬁrmed by FACS
analysis. We found that there was no signiﬁcant diﬀerence
at the expression levels at any time points (P=0.51, 0.41,
0.77, 0.54 for 2, 4, 6 and 8h, respectively) after synchro-
nization. Thus, the results in Figure 2D–G were limited
to cells expressing mRNA above the limit of detection.
Figure 2D depicts a LOI histogram for primary cytotro-
phoblasts. Although the distribution of cells exhibiting
Figure 2. Single cell LOI distributions of PLAGL1 and ZNF331 in human trophoblasts. Histograms show the percentage of cells exhibiting a given
LOI. In order to present data with positive and negative values of DCp based on a single allele and limit LOI to 0–100%, data with negative DCp
were calculated using the alternative allele. (A–B) LOI for primary PLAGL1 homozygous trophoblast controls. (C) LOI for ZNF331 heterozygotes
(scale limited to 35–100% LOI). (D–G) LOI of PLAGL1 heterozygotes with signiﬁcant LOI (35–100%). (D) Primary cytotrophoblasts; (E) Untreated
HTR8 cells. (F) HTR8 cells treated 1day with AZA. (G) HTR8 cells treated 2 days with AZA. The Fisher’s exact test was used to determine
signiﬁcance of the percentage of cells exhibiting LOI compared with the untreated control. (*P<0.05; **P<0.01).
Nucleic Acids Research, 2009,Vol.37, No. 21 7043LOI was wider than the distribution seen in Figure 2C,
the results still suggested a distribution centered at
 100% LOI.
Similar to the primary cytotrophoblasts, untreated
HTR8 cells showed a similar wide distribution of LOI
(Figure 2E). To follow up on the LOI results seen in
Table 1, HTR8 cells were treated with AZA for 1 or 2
days. The percentage of cells exhibiting LOI increased
signiﬁcantly (P<0.05 and P<0.01 at 1 and 2 days,
respectively), while the distribution remained wide and
centered at  100% LOI (Figure 2F and G). This distri-
bution is consistent with our hypothesis that LOI may
occur by an all-or-none process.
We examined two possible models for the interpretation
of the single cell data. The ﬁrst is the all-or-none LOI
model during which cells either are fully imprinted or
have completely lost their imprinting; the second is the
partial LOI model where the silenced allele exhibits incom-
plete activation (Figure 3A). In order to distinguish
between the models, we developed a mathematical model
based on transcriptional pulsing from the two alleles,
which simulated the variations of the mRNA synthesis
at the single cell level (19). Simulations for both models
(Figure 3B) used the equations described in Materials
and Methods section. The shapes of the computed
distributions were independent of pulse size, threshold
for detection or PCR error (Supplementary Figure S1).
The distribution of LOI observed in our experiments
(Figure 2D–G) ﬁt the all-or-none LOI model (left side of
Figure 2B). The Kolmogorov–Smirnov test showed a sta-
tistically signiﬁcant diﬀerence between experiment and
simulation based on the alternative model (P<0.05 for
each of 100 simulations), but no signiﬁcant diﬀerence
based on the all-or-none model (P>0.05 for each of 100
simulations).
DISCUSSION
We observed a low but signiﬁcant level of LOI in
both primary cytotrophoblasts and the cell line HTR8
(Table 1). In order to examine the mechanism of LOI,
we tested the eﬀects of two drugs that have been shown
to aﬀect epigenetic silencing. TSA aﬀects histone
acetylation and was previously shown to increase
PLAGL1 in cancer cell lines (14). Our results indicated
only a small eﬀect on expression, suggesting that regula-
tion of PLAGL1 by histone acetylation is less important in
placental trophoblasts. In contrast, treatment with the
methylation inhibitor AZA substantially increased both
expression and LOI.
If LOI were a function of the degree of methylation, this
LOI could reﬂect heterogeneity in methylation among
Figure 3. Models for the distributions of LOI in single cells. Simulations of single cell LOI distributions in 2000 cells were presented as histograms of
cell counts with diﬀerent percentage of LOI. The format for data presentation is the same as in Figure 2. (A) In the all-or-none model, we deﬁned
two distinct populations of cells: fully imprinted or having completely lost imprinting in the minor allele. In the partial LOI model, the transcription
of the minor allele is less eﬃcient than the major allele in each cell. (B) Simulated LOI distributions in single cells for each model (left side: all-or-
none model; right side: partial LOI model).
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LOI. We hypothesized, however, that LOI was an all-or-
none phenomenon, with LOI reﬂecting only the fraction
of cells expressing both alleles. Testing of this hypothesis
requires a functional assay of single cell LOI based on
transcriptional proﬁling.
We examined the eﬀect of AZA treatment on expression
and LOI at the single cell level. PLAGL1 was expressed at
low levels ( 0.2% of ACTB expression levels, see Table 1),
with expression unaﬀected by synchronization of the cells.
Expression increased with AZA treatment. Our single
cell measurements showed highly heterogeneous LOI
distributions in both human primary cytotrophoblasts
and HTR8 cells. The AZA treatment increased the
number of cells exhibiting high LOI, while the heteroge-
neity among single cells remained the same. The median
LOI remained close to 100%, consistent with our hypoth-
esis that LOI was an all-or-none phenomenon. It should
be noted that a process with many steps (e.g. loss of
methylation at individual sites) would be consistent with
all-or-none behavior if there is a one rate-determining step
that governs the switch from imprinted to nonimprinted
expression.
We examined the possibility that the PCR reaction
contributed signiﬁcantly to the wide distribution in LOI
seen at the single cell level. However, the rise in the
variance with serial dilution of template could be
accounted for by the expected variability in pipetting
small numbers of molecules. Thus, we proposed that the
large variation in single cell LOI measurements reﬂected
the stochastic nature in expression between the two alleles
and among the single cells. ZNF331 (Figure 2C), which is
expressed at a 2- to 4-fold higher level in total RNA than
PLAGL1, was detectable in all the cells yet showed signif-
icant cell-to-cell LOI variation. The fact that PLAGL1
mRNA levels in 60% of the cells were below the detection
limit suggested an even greater cell-to-cell variation in
expression, possibly due to transcriptional pulsing (32).
Herein, we proposed a transcription pulsing model to
show that transcriptional pulsing could also contribute
to chromosome to chromosome variation in expression
which would be reﬂected in a wide distribution of LOI
among cells that are expressing both alleles. Stochastic
expression by transcriptional pulsing will not aﬀect the
observed mean LOI at 100%, which is the important
parameter for supporting the all-or-none hypothesis for
LOI for PLAGL1 in trophoblasts. All-or-none LOI leads
to a second distinct cell population which could have a
selective advantage, leading to widespread LOI in normal
tissues, such as the placenta (8) or in neoplastic cells (11).
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